Post-exposure vaccination with the vaccine candidate Bacillus Calmette–Guérin ΔureC::hly induces superior protection in a mouse model of subclinical tuberculosis

Martin Gengenbacher; Peggy Kaiser; Stefanie Schuerer; Doris Lazar; Stefan H.E. Kaufmann

doi:10.1016/j.micinf.2016.03.005

Post-exposure vaccination with the vaccine candidate Bacillus Calmette–Guérin ΔureC::hly induces superior protection in a mouse model of subclinical tuberculosis

Martin Gengenbacher
, Peggy Kaiser
, Stefanie Schuerer
, Doris Lazar
, Stefan H.E. Kaufmann

Center for Discovery and Innovation

Max Planck Institute for Infection Biology

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

The tuberculosis vaccine BCG ΔureC::hly is the most advanced BCG replacement candidate in phase II clinical development. Here we assess the protective capacity of the construct administered to mice as homologous prime-boost vaccine prior Mycobacterium tuberculosis infection and as post-exposure vaccine. Multiple immunization did not improve the superior protection of BCG ΔureC::hly over BCG. Animals with subclinical tuberculosis were better protected when vaccinated with BCG ΔureC::hly as compared to BCG. Our findings suggest further consideration of BCG ΔureC::hly as post-exposure vaccine.

Original language	English
Pages (from-to)	364-368
Number of pages	5
Journal	Microbes and Infection
Volume	18
Issue number	5
DOIs	https://doi.org/10.1016/j.micinf.2016.03.005
State	Published - 1 May 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

BCG
Post-exposure vaccination
VPM1002

Access to Document

10.1016/j.micinf.2016.03.005

Cite this

@article{3591e9de1d4c4ca78485b0f67745f621,

title = "Post-exposure vaccination with the vaccine candidate Bacillus Calmette{\textendash}Gu{\'e}rin ΔureC::hly induces superior protection in a mouse model of subclinical tuberculosis",

abstract = "The tuberculosis vaccine BCG ΔureC::hly is the most advanced BCG replacement candidate in phase II clinical development. Here we assess the protective capacity of the construct administered to mice as homologous prime-boost vaccine prior Mycobacterium tuberculosis infection and as post-exposure vaccine. Multiple immunization did not improve the superior protection of BCG ΔureC::hly over BCG. Animals with subclinical tuberculosis were better protected when vaccinated with BCG ΔureC::hly as compared to BCG. Our findings suggest further consideration of BCG ΔureC::hly as post-exposure vaccine.",

keywords = "BCG, Post-exposure vaccination, VPM1002",

author = "Martin Gengenbacher and Peggy Kaiser and Stefanie Schuerer and Doris Lazar and Kaufmann, \{Stefan H.E.\}",

note = "Publisher Copyright: {\textcopyright} 2016 Institut Pasteur",

year = "2016",

month = may,

day = "1",

doi = "10.1016/j.micinf.2016.03.005",

language = "English",

volume = "18",

pages = "364--368",

journal = "Microbes and Infection",

issn = "1286-4579",

publisher = "Elsevier Masson s.r.l.",

number = "5",

}

TY - JOUR

T1 - Post-exposure vaccination with the vaccine candidate Bacillus Calmette–Guérin ΔureC::hly induces superior protection in a mouse model of subclinical tuberculosis

AU - Gengenbacher, Martin

AU - Kaiser, Peggy

AU - Schuerer, Stefanie

AU - Lazar, Doris

AU - Kaufmann, Stefan H.E.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The tuberculosis vaccine BCG ΔureC::hly is the most advanced BCG replacement candidate in phase II clinical development. Here we assess the protective capacity of the construct administered to mice as homologous prime-boost vaccine prior Mycobacterium tuberculosis infection and as post-exposure vaccine. Multiple immunization did not improve the superior protection of BCG ΔureC::hly over BCG. Animals with subclinical tuberculosis were better protected when vaccinated with BCG ΔureC::hly as compared to BCG. Our findings suggest further consideration of BCG ΔureC::hly as post-exposure vaccine.

AB - The tuberculosis vaccine BCG ΔureC::hly is the most advanced BCG replacement candidate in phase II clinical development. Here we assess the protective capacity of the construct administered to mice as homologous prime-boost vaccine prior Mycobacterium tuberculosis infection and as post-exposure vaccine. Multiple immunization did not improve the superior protection of BCG ΔureC::hly over BCG. Animals with subclinical tuberculosis were better protected when vaccinated with BCG ΔureC::hly as compared to BCG. Our findings suggest further consideration of BCG ΔureC::hly as post-exposure vaccine.

KW - BCG

KW - Post-exposure vaccination

KW - VPM1002

UR - https://www.scopus.com/pages/publications/84961899520

U2 - 10.1016/j.micinf.2016.03.005

DO - 10.1016/j.micinf.2016.03.005

M3 - Article

C2 - 26994939

AN - SCOPUS:84961899520

SN - 1286-4579

VL - 18

SP - 364

EP - 368

JO - Microbes and Infection

JF - Microbes and Infection

IS - 5

ER -

Post-exposure vaccination with the vaccine candidate Bacillus Calmette–Guérin ΔureC::hly induces superior protection in a mouse model of subclinical tuberculosis

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this